Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Diseases, Vascular » Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Vasculitis » Systemic Vasculitis » Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Description
Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls. MeSH
Hierarchy View
Subtype Terms (3)
Churg-Strauss Syndrome
17 drugs (15 approved, 2 experimental)
Granulomatosis with Polyangiitis
33 drugs (28 approved, 5 experimental)
Microscopic Polyangiitis
16 drugs (14 approved, 2 experimental)
Phase 4 Indicated Drugs (5)
Phase 1 Indicated Drugs (7)
Other Experimental Indicated Drugs (4)
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (17)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
